Blue water vaccines announces signing of sponsored research agreement with the university of texas health science center at san antonio to initiate non-human primate study for live attenuated, orally delivered chlamydia vaccine

Cincinnati, april 12, 2023 (globe newswire) -- blue water vaccines inc. (“bwv” or “blue water vaccines” or the “company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the signing of a sponsored research agreement (the “agreement”) with the university of texas health science center at san antonio (“ut health science center san antonio”) to fund a non-human primate (“nhp”) study to evaluate the efficacy of bwv-401, a live attenuated, orally delivered chlamydia vaccine.
BWV Ratings Summary
BWV Quant Ranking